Literature DB >> 7627155

A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies.

T K Nikula1, M J Curcio, M W Brechbiel, O A Gansow, R D Finn, D A Scheinberg.   

Abstract

A rapid, single vessel method for the preparation of clinical grade chelate conjugated monoclonal antibodies has been developed. By use of an Amicon concentrator with reservoir, each of the steps necessary for the preparation of the conjugated drug may be performed in a single vessel. Advantages include reduced risk of metal, pyrogen and bacterial contamination; buffer exchanges are achieved rapidly and efficiently using a continuous dilution method. The radiolabeling efficiency, the radiochemical purity, the total immunoreactivity and the affinity of the final product have been evaluated in the production of CHXA-DTPA-chelate conjugated HuM195. The characteristics compare favorably to those achieved using our conventional synthetic methods.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7627155     DOI: 10.1016/0969-8051(94)00126-5

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  19 in total

1.  Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.

Authors:  Mohanambe Lingappa; Hong Song; Sarah Thompson; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2010-07-22       Impact factor: 12.701

2.  177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.

Authors:  Christof Seidl; Christine Zöckler; Roswitha Beck; Leticia Quintanilla-Martinez; Frank Bruchertseifer; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-12       Impact factor: 9.236

3.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

4.  Antitumor immunity induced after α irradiation.

Authors:  Jean-Baptiste Gorin; Jérémie Ménager; Sébastien Gouard; Catherine Maurel; Yannick Guilloux; Alain Faivre-Chauvet; Alfred Morgenstern; Frank Bruchertseifer; Michel Chérel; François Davodeau; Joëlle Gaschet
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

5.  Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.

Authors:  Christof Seidl; Hedwig Schröck; Sabine Seidenschwang; Roswitha Beck; Ernst Schmid; Michael Abend; Karl-Friedrich Becker; Christos Apostolidis; Tuomo K Nikula; Elisabeth Kremmer; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

6.  Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

Authors:  Todd L Rosenblat; Michael R McDevitt; Deborah A Mulford; Neeta Pandit-Taskar; Chaitanya R Divgi; Katherine S Panageas; Mark L Heaney; Suzanne Chanel; Alfred Morgenstern; George Sgouros; Steven M Larson; David A Scheinberg; Joseph G Jurcic
Journal:  Clin Cancer Res       Date:  2010-09-21       Impact factor: 12.531

7.  Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.

Authors:  Sebastian Knör; Sumito Sato; Timo Huber; Alfred Morgenstern; Frank Bruchertseifer; Manfred Schmitt; Horst Kessler; Reingard Senekowitsch-Schmidtke; Viktor Magdolen; Christof Seidl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-22       Impact factor: 9.236

8.  In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.

Authors:  Douglas W Schneider; Tara Heitner; Bruno Alicke; David R Light; Kirk McLean; Noboru Satozawa; Gordon Parry; Jeongsoo Yoo; Jason S Lewis; Renate Parry
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

9.  213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.

Authors:  Hong Song; Karineh Shahverdi; David L Huso; Caroline Esaias; James Fox; Alyson Liedy; Allison Liedy; Zhe Zhang; R Todd Reilly; Christos Apostolidis; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

10.  Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

Authors:  Marcus P Kelly; Sze Ting Lee; F-T Lee; Fiona E Smyth; Ian D Davis; Martin W Brechbiel; Andrew M Scott
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.